Our findings are consistent with previous studies that have demonstrated the tumoricidal effects of RC48 on gastric cancer and breast carcinoma cell lines, xenograft models, and patient-derived xenograft (PDX) models with HER2 overexpression, even in cases with moderate to low expression of HER2 [21–23]. This evidence concerns the gene ERBB2 and gastric cancer.